CAR T-Cell Therapy: New Therapeutic Immunotherapy Innovation in Cancer
Abstract
Immunotherapy is treatment that uses person’s own immune system to fight against cancer. It can
boost or change the working of immune system so that it can find and attack cancer. T-cells are
immune system cells that play very important role in the body’s immune system to fight against the
disease. These cells help the immune system, respond to a disease and directly kill diseased cells.
Immunotherapy drugs are now approved for treatment of multiple cancer types either as first-line
treatment or when standard first-line treatment has failed. The FDA has recently approved the anti-
PD-1 antibody pembrolizumab for the treatment of any unresectable solid tumors.
Full Text:
PDFReferences
FDA News Release. FDA approves first cancer treatment for any solid tumor with a specific
genetic feature. Accessed on 30 Oct 2017.
American Society of Clinical Oncology (ASCO) ASCO Annual Meeting 2019: Immunotherapy
for lung cancer, gastrointestinal cancers and targeted therapy for breast cancer. Accessed at
https://www.cancer.net/blog/2019-06/asco-annual-meeting-2019-immunotherapy-lung-cancer-
gastrointestinal-cancers-and-targeted-therapy on December 19, 2019.
Bayer VR, Davis ME, Gordan RA, et al. Chemotherapy and Immunotherapy Guidelines and
Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 2019: 149–89.
National Cancer Institute (NCI). CAR T cells: Engineering patients’ immune cells to treat their
cancers. Available at: http://www.cancer.gov.
Porter DL, Maloney DG. Cytokine release syndrome (CRS). Accessed at
https://www.uptodate.com/contents/cytokine-release-syndrome-crs on April 01, 2021. Last
Revised: April 5, 2021.
Hedge PS, Karanikas V, Evers S. The where, the when and how of immune monitoring for cancer
immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016; 22: 1865–74.
TF Gajewski. The next hurdle in cancer immunotherapy: overcoming the non-T-cell-inflamed
tumor microenvironment. Semin Oncol. 2015; 42: 663–71.
Riddell SR, Sirvastava S. CAR T cell therapy: challenges to bench to bedside efficacy, J
Immunol. 2018, Jan 15; 200(2): 459–68.
Bonifant CL, Jakson HJ, Curran KJ. Toxicity and management in CAR T-cell therapy, 2016; 3.
Han D, Xu Z, Zhuang Y, Qian Q. Current progress in CAR T-cell therapy for hematological
malignancies; J Cancer. 2020; 12(2): 326–34.
Refbacks
- There are currently no refbacks.